A new therapy to prevent the 
progression of COVID-19

Biomarker and AI-supported FX06 therapy to prevent the progression from mild and moderate to severe stages of COVID-19
10 M €
ALLOCATED BUDGET
17
PARTNERS
13
EUROPEAN COUNTRIES
9
HOSPITALS
3
SMEs

The aim of the COVend Consortium is to deliver a new effective therapy against SARS-CoV-2 for the clinical management of the COVID-19 disease.

The COVend Consortium sets up to prevent COVID-19 progression to severe disease status by targeting endothelial dysfunction.

Some of the technologies involved in the process will be OMICs technologies for biomarker profiling, research on endothelial cell damage and AI for Data Analytics and modelling. 

From Ebola to COVID-19

Having cured a patient with Ebola, it was clear to Prof. Zacharowski that FX06 could also be beneficial against COVID-19.

News

Ethics Go Ahead for COVend

Submissions to Competent Authorities and Ethics Committees for IXION study Starting in December 2021, our COVend researchers submitted to both their Competent Authority and Ethics

Read More »